Day: May 19, 2023

Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting

RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency...

BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share

BBS-Bioactive Bone Substitutes Oyj, Company release, 19 May 2023 at 12.00 p.m. EEST BBS-Bioactive Bone Substitutes Oyj: The subscription period...

error: Content is protected !!